2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre C
Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Biological Therapies, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

318 Large cell transformation in mycosis fungoides/Sézary syndrome: Clinical and pathologic predictors, outcomes, and treatment patterns in the U.S. BEACON-CTCL cohort

Haris Qureshi, MD, Arjun Ravishankar, MBBS2, Darina Paulino3, Neha Akkad, MD4, Toan Bui5, Marcus Watkins, PhD6, Anne Beaven, MD7, Ann Ayzman, MD8, Ahmad Kiwan, MD9, Allison C Rosenthal, DO10, Aaron Mangold, MD11, Swaminathan P. Iyer, MD12, Eric Mou, MD13, Carlos Torres-Cabala, MD14, Paola Ghione, MD, MS15, Vincent Liu16, Auris O. Huen, MD, PharmD17, Kathryn Elise Keller18, Jane Scribner19, Neha Mehta-Shah, MD, MSCI20, Michael Girardi, MD, FAAD21, Francine Foss, MD22, Sima Rozati, MD PhD23, Pamela Allen, MD24, Tarsheen Sethi, MD25
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Emory University, Atlanta, Georgia, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
11 Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 MUSC College of Medicine, Charleston, South Carolina, United States
19 MUSC College of Medicine, Charleston, South Carolina, United States
20 Washington University School of Medicine, St. Louis, Missouri, United States
21 Yale School of Medicine, New Haven, Connecticut, United States
22 Yale School of Medicine, New Haven, Connecticut, United States
23 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
24 Emory University, Atlanta, Georgia, United States
25 Yale School of Medicine, New Haven, Connecticut, United States

Background:
Large cell transformation (LCT) is an aggressive clinicopathologic evolution of mycosis fungoides/Sézary syndrome (MF/SS). Predictors of transformation and contemporary post-LCT outcomes remain incompletely defined. In a large U.S. multicenter cohort of CTCL patients (U.S. BEACON-CTCL), we evaluated factors associated with LCT and characterized treatment response and survival.  

Methods:
We conducted a retrospective multicenter study of adults diagnosed with MF/SS during 2000–2024. LCT was defined by biopsy showing >25% large cells at any involved site. Predictors of LCT were evaluated using multivariable logistic regression. Overall survival (OS) from diagnosis and from first LCT biopsy was estimated using Kaplan-Meier methods and modeled using Cox regression. The primary post-LCT model included first brentuximab vedotin (BV)-based systemic therapy (BV or BV-CHP), LCT at diagnosis, extracutaneous transformation, age, sex, and race. Responses were assessed among evaluable patients. MF-LCT versus SS-LCT was defined by phenotype at transformation.

Results:
Of 1779 pts evaluated, 254 had LCT. Advanced stage at diagnosis (IIB–IV vs I–IIA) was associated with increased risk of LCT (adjusted odds ratio [aOR], 2.80; 95% CI, 2.10–3.73; p<0.001), whereas female sex was associated with lower risk (aOR, 0.70; 95% CI, 0.52–0.94; p=0.018). In patients in whom CD30 was assessed (N=606), advanced disease (aOR, 3.26; 95% CI, 2.10–5.04; p<0.001) and CD30 positivity (defined as ≥1% on immunohistochemistry) at diagnosis (aOR, 3.60; 95% CI, 2.35–5.52; p<0.001) were independently associated with LCT. LCT was associated with inferior OS (measured from diagnosis) after adjustment for stage, age, sex, and race (hazard ratio [HR], 1.66; 95% CI, 1.36–2.03; p<0.001); in a 12-month landmark analysis, early LCT remained an adverse prognostic marker (HR, 2.19; 95% CI, 1.63–2.96; p<0.001).

Of 246 patients with MF-LCT or SS-LCT, the median time from diagnosis to LCT was 22.9 months (95% CI, 16.7–28.5; N=241). Of these, 202 had systemic therapy and 64 (31.7%) received BV-based therapy. Of 175 response evaluable LCT patients, first treatment overall response rate (ORR) was 52.6%. First-line BV therapy was associated with a higher ORR than non-BV therapy (68.3% vs 43.8%; p=0.002).

At a median follow up of 60 months, the median OS after LCT diagnosis was 36.3 months (95% CI, 31.2–42.5. In the complete-case adjusted model (N=151; 106 deaths), BV-based first therapy was associated with longer OS after LCT diagnosis (HR, 0.45; 95% CI, 0.28–0.74; p=0.001), while Black race was associated with inferior OS versus White race (HR, 1.77; 95% CI, 1.15–2.71; p=0.009). Time of LCT onset, extracutaneous site, age, and sex were not independently associated with OS. Among 209 patients with known phenotype and valid OS, SS-LCT had shorter median OS than MF-LCT (22.6 vs 42.5 months; unadjusted HR, 1.76; 95% CI, 1.24–2.50; p=0.001).

Conclusions:
Advanced-stage disease and CD30 positivity at diagnosis identified patients at increased risk of LCT, and transformation was independently associated with inferior survival. After LCT, BV-based first therapy was associated with higher response rate and longer OS. LCT in SS patients was associated with inferior unadjusted survival, and Black race remained independently associated with worse outcomes. These findings support surveillance and early recognition of LCT, particularly in CD30+ patients and support the use of BV-based therapies following LCT.

Haris Qureshi, MD: No relevant conflicts of interest to declare.